(L-R) Peter Rohweder, Kevan Shokat, Ziyang Zhang, Daniel Green, Charly Craik
The scientist who pioneered KRAS drugs has a new idea about making them more powerful
It’s only been nine years since Kevan Shokat’s group at the University of California, San Francisco published the seminal paper breaking the “undruggable” spell thought to ensnare KRAS, one of the most common oncogenes. In less than a decade — breakneck speed by drug development standards — the space went from utterly barren to having one approved drug, plus a close rival ready to duke it out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
